DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 21-38 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 12,239,451 (‘451). Although the claims at issue are not identical, they are not patentably distinct from each other because the ‘451 patent discloses a kit comprising: a non-placebo challenge meal formulation comprising allergen, wherein the allergen is present in the non-placebo challenge meal formulation in an amount of more than about 10% w/w and less than about 25% w/w; and a placebo challenge meal formulation comprising no food allergen, wherein the placebo challenge meal formulation comprises an additive present in an amount of from about 0.05% w/w to less than 0.9% w/w of the placebo challenge meal formulation, wherein the additive is selected from the group consisting of: maltodextrin, dextrin, cyclodextrin and combinations thereof.
Thus, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to obtain the claimed invention given the claims of the ‘451 patent. This is because the ‘451 patent discloses a kit similar to the present invention, namely, a kit that comprises a placebo challenge meal formulation comprising no food allergen; and a non-placebo challenge meal formulation comprising an allergen, wherein the allergen is present in the non-placebo challenge meal formulation in an amount of more than 10% w/w and less than 25% w/w.
Claims 21-38 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-15 of U.S. Patent No. 11,439,342 (‘342). Although the claims at issue are not identical, they are not patentably distinct from each other because the ‘342 patent claims a kit comprising: a placebo challenge meal formulation comprising no food allergen; and a non-placebo challenge meal formulation comprising an allergen, wherein the allergen is present in the non-placebo challenge meal formulation in an amount of more than 10% w/w and less than 25% w/w; wherein the placebo and non-placebo challenge meal formulations each comprise: 20% w/w to 60% w/w of a matrix formation component, wherein the matrix formation component comprises a starch and a sucrose; 10% w/w to 35% w/w of a texturizing component, wherein the texturizing component comprises an oil component and a surfactant; and 10% w/w to 45% w/w of a flavor/color masking component; and wherein the placebo challenge meal formulation comprises an additive present in an amount of from about 0.05% w/w to about 1.0 w/w of the placebo food challenge meal formulation, and wherein the additive is selected from the group consisting of: maltodextrin, dextrin, cyclodextrin and combinations thereof, and wherein, upon reconstitution with water, the placebo and the non-placebo challenge meal formulations each form a mousse. Peanut allergen is found in claim 4. Maltodextrin is found in claim 5. Polysorbate 60 is found in claim 9. The claimed flavor and/or color masking is found in claims 11-15.
Thus, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to obtain the claimed invention given the claims of the ‘342 patent. This is because the ‘342 patent discloses a kit similar to the present invention, namely, a kit that comprises a placebo challenge meal formulation comprising no food allergen; and a non-placebo challenge meal formulation comprising an allergen, wherein the allergen is present in the non-placebo challenge meal formulation in an amount of more than 10% w/w and less than 25% w/w.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 21-40 are rejected under 35 U.S.C. 103 as being unpatentable over Raff US 2015/0343075, in view of Walser et al. US 2016/0030289.
Raff teaches a placebo composition that is similar in color and texture compared to a composition comprising peanut flour, and which comprises: one or more glidants in an amount of from about 0.01% to about 10% w/w of the placebo composition, one or more lubricants in an amount of from about 0.01% to about 10% w/w of the placebo composition, one or more diluents in an amount of from about 1% to about 99% w/w of the placebo composition, and one or more colorants in an amount of from about 0.01% to about 10% w/w of the placebo. See abstract and paragraphs 0037-0039. Diluents include surfactant, starch and sucrose is found in paragraphs 0046 and 0068. Maltodextrin and cyclodextrin and dextrin are found in paragraphs 0046, 0068-0070.
Raff does not specifically teach the peanut flour composition comprising the claimed amount of peanut.
Walser teaches a low dose capsule formulation comprising, (a) mixing peanut flour and diluent in a first blend; (b) adding about 45% of diluent in a second blend; (c) adding remaining diluent in a third blend; (d) adding a glidant and/or lubricant in a final blend; and (e) encapsulating blended powder in a capsule. In one embodiment, the diluent of step (a) comprises starch or lactose, microcrystalline cellulose (Avicel.RTM.), or dicalcium phosphate. In another embodiment, the diluent of step (b) and/or (c) comprises starch, lactose, microcrystalline cellulose (Avicel.RTM.), or dicalcium phosphate. In another embodiment, the glidant of step (d) glidant of step (d) comprises colloidal silicon dioxide (Cab-O-Sil), talc (e.g., Ultra Talc 4000), or combinations thereof. In another embodiment, the lubricant of step (d) comprises magnesium stearate. In one non-limiting example, the glidant comprises Cab-O-Sil. In one embodiment, step (d) comprises adding a glidant or a lubricant. See paragraph 0006. Peanut flour in the capsule is in an amount ranging from 10-15% is found in paragraph 0050.
Thus, it would have been obvious to one of ordinary skill in the art at the time the invention was made to include the peanut flour capsule taught in Walser in the kit with the expectation of at least similar result. This is because Walser teaches using low dose peanut capsule for oral desensitization is known in the art, and this is because Raff teaches the desirability for preparing a kit that comprises both a placebo capsule and a peanut flour capsule for the treatment of peanut allergy.
Claims 21-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Raff US 2015/0343075 A1, in view of Wood et al. WO 2013/173697A1.
Raff teaches a placebo composition that is similar in color and texture compared to a composition comprising peanut flour, and which comprises: one or more glidants in an amount of from about 0.01% to about 10% w/w of the placebo composition, one or more lubricants in an amount of from about 0.01% to about 10% w/w of the placebo composition, one or more diluents in an amount of from about 1% to about 99% w/w of the placebo composition, and one or more colorants in an amount of from about 0.01% to about 10% w/w of the placebo. See abstract and paragraphs 0037-0039. Diluents include surfactant, starch and sucrose is found in paragraphs 0046 and 0068. Maltodextrin and cyclodextrin and dextrin are found in paragraphs 0046, 0068-0070.
Raff does not teach the claimed non-placebo challenge meal formulation.
Wood teaches an oral thin film containing allergens. See abstract. The film comprises less than about 25%w/w allergen extract such as peanut. See paragraphs 0015, 0032 and Example 1. The film further comprising about 0.005% to 5%w/w sweetener such as dextrin.
Thus, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to optimize the teaching of Raff to include the thin film allergen composition of Wood with the expectation to obtain a kit with at least a placebo and a non-placebo composition similar to taste and look. This is because Raff teaches the desirability for making a kit comprising a placebo composition that is similar in color and texture compared to a composition comprising peanut flour. This is because Wood teaches the use of a non-placebo composition comprising dextrin in the claimed amount is known and useful in the art. Therefore, one of the ordinary in the art would have been motivated to include an allergen treating composition of Wood in the kit and in view of the teaching of Raff, making the non-placebo to mimic the film, hence, having a composition comprising dextrin in the claimed amount.
Correspondence
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSAN T TRAN whose telephone number is (571)272-0606. The examiner can normally be reached Monday-Friday, 8:30 am-5:30 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, ROBERT A. WAX can be reached on 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SUSAN T TRAN/Primary Examiner, Art Unit 1615